A5050848065- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Inflammatory Biomarkers in Disease Prognosis
- Gastric Cancer Management and Outcomes
- Head and Neck Cancer Studies
- Bone and Joint Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Oral and Maxillofacial Pathology
- Tumors and Oncological Cases
- Peptidase Inhibition and Analysis
- Central Venous Catheters and Hemodialysis
- Gestational Trophoblastic Disease Studies
- Vascular Malformations and Hemangiomas
- Chemotherapy-related skin toxicity
- Inflammatory Myopathies and Dermatomyositis
- Frailty in Older Adults
- Neuroendocrine Tumor Research Advances
- Magnesium in Health and Disease
- Neutropenia and Cancer Infections
Teikyo University
2017-2025
Teikyo University Hospital
2021-2023
Udayana University
2021
National Cheng Kung University Hospital
2021
Rationale: A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF).Objectives: This study aimed to assess the safety and efficacy of carboplatin, etoposide, nintedanib combination therapy unresectable SCLC IPF.Methods: The NEXT-SHIP is a multicenter, single-arm, phase 2 trial IPF (Japan Registry Clinical Trials registry number jRCTs031190119). patients received (150 mg twice daily). primary...
Abstract Background Atezolizumab is a programmed death‐ligand 1 (PD‐L1) targeted monoclonal antibody that inhibits PD‐L1 interacting with its receptors PD‐1 and B7‐1, thereby enhancing anticancer immunity. Some real‐world efficacy safety studies of anti‐PD‐1 have been previously reported. However, there no reports investigating the atezolizumab monotherapy in clinical practice which focused on performance status previous treatment. Methods We retrospectively reviewed consecutive advanced...
Background: The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear. Objective: We aimed to evaluate the characteristics survival this therapy. Design: This was sub-analysis retrospective multicenter NINJA study. Methods: Among 93 patients enrolled in study, subanalysis included 75 with baseline serum magnesium concentrations. Results: incidence grade ⩾2 18.0% normal concentrations 42.8% those low ( p =...
Background: Skin disorders are major adverse events associated with necitumumab plus gemcitabine and cisplatin (Neci + GC) administration. However, the prognostic effect of skin in patients lung squamous cell carcinoma (LSCC) administered Neci GC is unclear. Objectives: We examined this LSCC, usefulness minocycline Design: This was a sub-analysis retrospective multicenter NINJA study. Methods: performed landmark survival analysis according to presence at Day 30 treatment for treating...
The patient was a 69-year-old male who had started experiencing acute-onset pain in both shoulder joints and edema of hands feet. His symptoms progressively worsened within 1 month. Laboratory data indicated elevated CRP erythrocyte sedimentation rate despite the normal range antinuclear antibodies rheumatoid factor organ function. Furthermore, imaging hand synovitis without bone erosions. Meanwhile, chest CT revealed lung tumor, leading to diagnosis primary adenocarcinoma with EGFR mutation...
Abstract Background Osimertinib is one of the standard first-line treatments for advanced non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations, because it achieves significantly longer progression-free survival (PFS) than conventional (hazard ratio: 0.46). However, efficacy and safety osimertinib as a treatment aged ≥75 years remain unclear. Methods This phase II study was performed to prospectively investigate elderly EGFR mutation-positive cancer....
Neutrophil-to-lymphocyte ratio (NLR) has recently attracted attention as a prognostic predictor in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors (ICIs). However, the utility of NLR relation to cytotoxic anticancer drugs or molecular targeted remains unclear. We determined if could predict treatment efficacy and prognosis NSCLC drugs, well ICIs, cross-sectional manner.Of 658 advanced received first-line systemic our hospital between 2008 2019, 312...
In lung cancer, several potential mechanisms of intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been explored, including mesenchymal-epithelial transition (MET) signaling pathway activation. On the other hand, vascular endothelial (VEGF) production EGFR-mutated cancer cells is stimulated by predominantly activated MET pathway. Therefore, inhibition VEGF axis as downstream target seems promising. Here, for first time, we...
Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety patients with brain metastases are still unclear.Eligible included those NSCLC measurable asymptomatic that progressed after chemotherapy. Patients were intravenously administered ramucirumab (10 mg/kg) (60 mg/m2) every 21-day cycle.Due to difficulties in accumulating the planned 65 participants, enrollment was terminated early...
Background: Central venous catheters (CVCs) are sometimes superior to peripheral vascular access for chemotherapy. line-associated bloodstream infections (CLABSIs) an important complication of CVCs in
The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high efficacy and tolerability CRT with cisplatin plus S-1 (SP), no prospective study using durvalumab after SP-based has been reported.
A 50-year-old man with lung adenocarcinoma (c-T1aN2M1b) experienced reddish purpura mainly on the lower legs after receiving 12 cycles of second-line chemotherapy docetaxel. There was tumor enlargement computed tomography performed to assess therapeutic response, so paraneoplastic IgA vasculitis considered. diagnosed based a biopsy skin lesion and histology an upper gastrointestinal hemorrhagic mucosal erosion. As can lead serious or systemic complications, should be considered as...
For sebaceous carcinoma (SC), a rare malignant tumor, no standard chemotherapy regimen for patients with distant metastasis has been studied. We experienced case of eyelid SC multiple lung metastases that responded to combination carboplatin and paclitaxel 11-month progression-free survival (PFS). This patient also second-line treatment docetaxel, another taxane, 7-month PFS, resulting in at least 18 months the time reporting. report shows taxane-based may be effective advanced SC, which...
A 40-year-old man with a diagnosis of lung adenocarcinoma (cT4N3M1c, stage IVB) experienced worsening lymphangitic carcinomatosis in the right and pleural effusion after receiving 1 cycle first-line chemotherapy consisting cisplatin pemetrexed. Bevacizumab was thus added from second cisplatin-pemetrexed regimen, leading to marked improvement pulmonary decrease effusion. Subsequently, maintenance therapy pemetrexed bevacizumab continued, successfully long-term progression-free survival....
Dacomitinib significantly improves progression-free survival and overall (OS) compared with gefitinib in patients non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations. However, dacomitinib often causes skin toxicities, resulting treatment discontinuation. We aimed to evaluate a prophylactic strategy for toxicity induced by dacomitinib.We performed single-arm, prospective, open-label, multi-institutional phase II trial comprehensive...
Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy tolerability of GCN in second-line or later treatment previously treated immune checkpoint inhibitors (ICIs) remain unknown.This multicenter, retrospective, cohort study assessed initiated between November 1, 2019 March 31, 2022 as to fourth-line LSqCC who had been pretreated ICIs. The primary end point was progression-free survival...
The patient was a 66-year-old woman. An induration of approximately 15 mm in size that accompanied redness palpable the umbilical fossa. She did not respond to 1-month antibiotic treatment provided by previous physician. For this reason, biopsy site performed with possibility neoplastic disease mind, resulting detection adenocarcinoma. Subsequent detailed whole-body examination revealed advanced gastric cancer and peritoneal dissemination, fossa diagnosed as direct infiltration from...
Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer treatment. Aprepitant is an antagonist neurokinin-1 receptor, through P activates pruritogens. Thus, aprepitant expected offer a promising option for treatment erlotinib-induced pruritus. However, appropriate schedule administration under...
The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as main reasons to preclude initiation durvalumab in multiple retrospective studies. However, transition rate failure proceed consolidation therapy with after CRT not evaluated prospectively. Although phase II studies Japan have shown high efficacy tolerability cisplatin +...
We encountered a case of primary lung cancer complicated with membranous nephropathy as nephrotic syndrome. Because treatment approaches vary greatly for and secondary syndrome, renal biopsy was performed diagnosis. Much time required to make definitive diagnosis opposed paraneoplastic Consequently, the subsequent chemotherapy ineffective caused significant toxicity due reduced performance status (PS) progression hypoalbuminemia. Therefore, it is imperative that be made initiated without...